Sulindac in familial adenomatous polyposis [3]

New England Journal of Medicine

Volumn 347, Issue 8, 2002, Pages 615-

  Levy, Rafael ^a  

^a Oncology Unit   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SULINDAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOMATOUS POLYP; ALLELE; COLON ADENOMA; DRUG EFFECT; FAMILIAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; LETTER; PRIORITY JOURNAL; RECTUM ADENOMA; TUMOR VOLUME; ADENOMA; COLON POLYPOSIS; COLON TUMOR; GENETICS; HUMAN; MUTATION; NOTE; ONSET AGE; TUMOR SUPPRESSOR GENE;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; GENES, APC; GERM-LINE MUTATION; HUMANS; SULINDAC;

EID: 0037158619     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200208223470816     Document Type: Letter

References (4)

1. Primary chemoprevention of familial adenomatous polyposis with sulindac
2. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients
3. The clinical correlates of a 3′ truncating mutation (codons 1982-1983) in the adenomatous polyposis coil gene
4. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps